We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Spark Therapeutics, Inc. (NASDAQGS: ONCE) to Roche (OTCQX: RHHBY). Under the terms of the transaction, Spark Therapeutics shareholders will receive US$114.50 per share.
The Spark merger investigation concerns whether the Board of Spark breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Roche is underpaying for Spark shares, thus unlawfully harming Spark shareholders.
To receive more information, please fill out the form.